CoChat
Sign Up
Cited by 146TGF-β signaling in diseasesGlioma Diagnosis and TreatmentT-cell and B-cell Immunology

The effect of transforming growth factor-β2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma

Jachimczak, Piotr, Bogdahn, Ulrich, Schneider, Jörg, Behl, Christian, Meixensberger, Jürgen, Apfel, Rainer, Dörries, Rüdiger, Schlingensiepen, Karl-Hermann +1 more·1993·Journal of Neurosurgery
DOI 10.3171/jns.1993.78.6.0944
Open this paper in CoChat — free account

Abstract

✓ This in vitro study was aimed at restitution of transforming growth factor (TGF)-β 2-mediated suppression of T-lymphocyte activation within malignant gliomas. In early-passage tumor cell cultures of two glioblastomas (HTZ-153 and HTZ-209) and one malignant astrocytoma classified as World Health Organization Grade III (HTZ-243), autologous peripheral blood mononuclear cells were activated by interleukin-lα and interleukin-2 in vitro (lymphokine-actived killer cells) and tested for cytotoxic and proliferative activity. In expression studies (Western blot and Northern hybridization) of all three tumors, TGF-β could be detected at the protein and messenger ribonucleic acid (mRNA) levels. A polyclonal anti-TGF-β neutralizing antibody did not enhance lymphocyte proliferation upon stimulation with tumor targets (3 H-thymidine incorporation) and slightly stimulated lymphocyte cytotoxicity against autologous target cells. Preincubation of target cells for 12 hours with TGF-β 2-specific phosphorothioate-anti-sense oligodeoxynucleotides (S-ODN's) did, however, enhance lymphocyte proliferation up to 2.5-fold and autologous tumor cytotoxicity up to 60%, compared to controls not treated with S-ODN's. Incubation of tumor cells with TGF-β 2-specific S-ODN's resulted in decreased TGF-β-specific immunoreactivity in cultured glioma cells, in reduced TGF-β 2 protein concentration (Western blot), and in a change in the expression pattern of TGF-β 2 mRNA's. These observations may have implications for in vivo and in vitro activation of a cellular immune response against autologous malignant glioma cells.

Integrity signals

Registry

Crossref · 10.3171/jns.1993.78.6.0944

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • These inhibitors do not target TGF-β receptors specifically, since they equally effectively inhibit related type I receptors for several other TGF-β-related proteins, such as activin, nodal and myostatin.

    “Additionally, they do not target TGF-β receptors specifically, since they equally effectively inhibit related type I receptors for several other TGF-β-related proteins, such as activin, nodal and myostatin293”

    From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [293]

Cites

Flagged first, then by citations

7 of the 48 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Related

Authors
Jachimczak, P., Bogdahn, U., Schneider, J., Behl, C., Meixensberger, J., Apfel, R., Dörries, R., Schlingensiepen, K.-H., & Brysch, W.
Affiliations
University of Würzburg (DE)
ORCID
Behl, Christian
Venue
Journal of Neurosurgery
Publisher
Journal of Neurosurgery Publishing Group (JNSPG)
Published
1993-06
Volume
78
Issue
6
Pages
944-951
ISSN
0022-3085 (ISSN-L)
DOI
10.3171/jns.1993.78.6.0944
OpenAlex
W2166484715
Cited by
146
References
48
Citations by year
2026: 2 · 2025: 2 · 2024: 1 · 2023: 2 · 2022: 1 · 2021: 4 · 2020: 3 · 2019: 1 · 2018: 2 · 2017: 2 · 2016: 1 · 2015: 4 · 2014: 1 · 2013: 4 · 2012: 6
FWCI
2.55
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of neurosurgery (publishedVersion)
  • PubMed (publishedVersion)
  • University of Regensburg Publication Server (University of Regensburg) (submittedVersion)
  • MPG.PuRe (Max Planck Society) (submittedVersion)
Funders
World Health Organization
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
  • Health Sciences › Medicine › Genetics › Glioma Diagnosis and Treatment
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
transforming growth factor-beta2, high-grade glioma, glioblastoma, malignant astrocytoma, T cell activation, immunosuppression, lymphokine-activated killer cells, tumor cell killing, TGF-beta mRNA expression, autologous tumor cells, cell-mediated immunity
MeSH terms
Antigens, Neoplasm, Brain Neoplasms, Glioma, Humans, Immunity, Cellular, Leukocytes, Mononuclear, Phenotype, RNA, Neoplasm, T-Lymphocytes, Cytotoxic, Tumor Cells, Cultured, Blotting, Northern, Blotting, Western, Antigens, CD, Killer Cells, Lymphokine-Activated, Transforming Growth Factor beta, Oligonucleotides, Antisense, Immunocompromised Host

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review